S&P 500 Industrials Sector SEC Filings — April 03, 2026

03-04-2026

Employees Provident Fund Board filed a 13F-HR report on April 3, 2026, disclosing total holdings of $2,923,831,590 across 45 equity positions as of December 31, 2015. Top holdings include Apple Inc ($252,437,374 for 2,398,227 shares), Wells Fargo & Co New Com ($158,361,389 for 2,913,197 shares), Microsoft Corp Com ($157,300,669 for 2,835,268 shares), Intel Corp Com ($127,463,105 for 3,699,945 shares), and Johnson & Johnson Com ($129,458,427 for 1,260,304 shares). All positions are reported with sole voting authority and no shared or other voting rights.

• ·Report period end date: 12-31-2015
• ·Filing date: 04-03-2026
• ·All 45 holdings reported as SH SOLE (sole voting authority) with 0 shared or other voting authority
• ·SEC file number: 028-26736

03-04-2026

Healthier Choices Management Corp. entered into an unsecured Loan Agreement with Sabby Volatility Warrant Master Fund, Ltd. on March 27, 2026, for general working capital purposes, as disclosed in an 8-K filing on April 3, 2026. The agreement provides for Advances via promissory Notes with a Scheduled Maturity Date of December 31, 2026, potentially extendable. No specific loan amounts, interest rates, or financial metrics are detailed in the provided filing excerpt.

• ·Loan is unsecured (Section 4.1).
• ·Scheduled Maturity Date: December 31, 2026 (potentially extendable per Section 2.4).
• ·SEC 8-K Items: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Exhibits).

03-04-2026

Health Catalyst, Inc. entered into a Transition Agreement with former CEO Daniel Burton on March 31, 2026, following his accelerated retirement from the CEO position on February 12, 2026, as previously reported in a Form 8-K on February 18, 2026. Under the agreement, Burton will serve as a strategic advisor until December 31, 2026, receiving an average monthly base salary of $10,000 starting March 1, 2026, in exchange for forfeiting all unvested restricted stock units eligible for vesting after March 2, 2026, and providing a general release of claims. This arrangement facilitates a smooth transition of his prior responsibilities.

• ·Transition Agreement dated March 31, 2026, attached as Exhibit 10.1
• ·Previous Form 8-K filed February 18, 2026, regarding Burton's retirement notice on February 12, 2026
• ·Strategic advisor role ends December 31, 2026

03-04-2026

Generation Income Properties, Inc. reported total revenue of $9,739,942 for FY 2025, slightly down 0.2% YoY from $9,762,636, with rental income up modestly 2.0% to $9,698,991 but offset by sharply lower other income. Net loss widened to $(6,389,000) from $(4,872,888), driven by higher interest expense (+35%) and total expenses up 12.3% to $16,727,857, though building expenses declined 5.4%; Core Adjusted FFO improved to $1,202,089 from $372,920, supported by a $1.94M gain on property sale and cash surge to $6.2M from investing inflows. Stockholders' equity turned to a $(4.2M) deficit from a $5.8M surplus amid rising redeemable non-controlling interests to $32.2M.

• ·Operating cash flow declined to $929,474 from $1,022,362 YoY.
• ·Investing cash inflow of $23,108,724 from property sale vs. $5,773,323 outflow prior year.
• ·Net cash used in financing activities $18,486,821 vs. provided $2,246,453.
• ·Basic & Diluted EPS $(2.00) vs. $(1.64).
• ·Redeemable Non-Controlling Interests increased to $32,187,864 from $26,664,545.

03-04-2026

GE Vernova Inc. (GEV) filed a DEFA14A Definitive Additional Materials proxy statement on April 03, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive proxy details, financial data, or voting matters are included in the provided filing header.

03-04-2026

Valley National Bancorp has filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting of Shareholders, scheduled virtually on May 18, 2026, at 9:00 a.m. ET. Key voting items include the election of 11 director nominees, an advisory vote to approve named executive officer compensation, and ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with the Board recommending 'FOR' on all proposals. Shareholders can vote by May 17, 2026, 11:59 PM ET (or May 13 for 401(k) shares) and request proxy materials by May 4, 2026.

• ·Virtual meeting link: www.virtualshareholdermeeting.com/VLY2026
• ·Voting platform: www.ProxyVote.com
• ·Material request methods: www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com (include control number)
• ·Includes reference to 2025 Annual Report to Shareholders

03-04-2026

Village Farms International, Inc. (VFF) announced a succession plan for Chief Financial Officer Stephen Ruffini, who will transition after 17 years of service to a new role leading M&A activities, remaining as CFO until a permanent replacement is identified. The company highlighted its strong financial position and growth strategy combining organic investments with accretive acquisitions. CEO Michael DeGiglio commended Ruffini's contributions, including NASDAQ uplisting and cannabis expansion.

• ·Hired as CFO in 2009; instrumental in NASDAQ uplisting, debt/equity financings, and cannabis expansion.
• ·Operates EU-GMP certified cannabis facility in Delta, British Columbia, exporting to international medical markets.
• ·Clean Energy division transforms landfill gas into renewable natural gas.

03-04-2026

GD Culture Group Limited held its 2026 annual meeting of stockholders on March 30, 2026, with 30,606,330 shares present or represented by proxy, constituting 50.37% of the 60,759,711 outstanding shares and a quorum. Stockholders elected all five director nominees (Xiao Jian Wang, Zihao Zhao, Lei Zhang, Yun Zhang, and Shuaiheng Zhang) with overwhelming majorities exceeding 99% 'for' votes in each case, ratified GGF CPA LTD as the independent auditor for fiscal years 2025 and 2026, and approved the adjournment proposal if needed. No significant opposition or failures were reported across all proposals.

• ·Proposal 1 votes: Xiao Jian Wang (For: 30,596,679; Against: 9,623; Abstain: 28); Zihao Zhao (For: 30,584,503; Against: 21,798; Abstain: 29); Lei Zhang (For: 30,419,989; Against: 186,312; Abstain: 29); Yun Zhang (For: 30,419,989; Against: 186,312; Abstain: 29); Shuaiheng Zhang (For: 30,402,696; Against: 203,605; Abstain: 29). No broker non-votes.
• ·Proposal 2 (auditor ratification): For 30,423,507; Against 182,153; Abstain 670. No broker non-votes.
• ·Proposal 3 (adjournment): For 30,419,966; Against 183,488; Abstain 2,876. No broker non-votes.
• ·Record date: March 4, 2026. Meeting held at 1:00 p.m. Eastern Time.

03-04-2026

InMed Pharmaceuticals Inc. filed a prospectus supplement on April 3, 2026, under its shelf registration statement on Form S-3 (File No. 333-294503, effective March 30, 2026), enabling sales of common shares pursuant to the At The Market Offering Agreement with H.C. Wainwright & Co., LLC (dated April 7, 2022, amended June 27, 2024) for an aggregate value of up to $1,213,648. A legal opinion from Norton Rose Fulbright Canada LLP affirming the validity of the shares is included as Exhibit 5.1. No sales have been reported at this time.

• ·Prospectus supplement dated April 2, 2026
• ·Sales Agreement originally dated April 7, 2022, amended June 27, 2024
• ·Form S-3 filed March 20, 2026, declared effective March 30, 2026

03-04-2026

Prosperity Bancshares Inc filed an S-4 registration statement for its merger with Stellar, under which each share of Stellar common stock will convert into $11.36 in cash and 0.3803 shares of Prosperity common stock at a fixed exchange ratio. The document emphasizes significant risks, including fluctuations in Prosperity's stock price affecting merger value, substantial transaction and integration costs, potential regulatory delays or conditions, and challenges in realizing synergies or retaining key employees. These factors could lead to adverse effects on Prosperity's operations, stock price, and failure to achieve expected benefits.

• ·Fixed exchange ratio of 0.3803 shares of Prosperity common stock per Stellar common share.
• ·Waiver of prior approval by the Federal Reserve Bank of Dallas obtained on March 17, 2026.
• ·Pending regulatory approvals from Federal Reserve Board or Federal Reserve Bank of Dallas, FDIC, and Texas Department of Banking.
• ·Excludes dissenting shares, treasury shares, and certain shares held by Stellar or Prosperity from conversion.

03-04-2026

National Bank Holdings Corporation (NBHC) filed its definitive proxy statement (DEF 14A) on April 3, 2026, for the 2026 Annual Meeting of Shareholders on May 7, 2026, at Vista Bank in Dallas, TX, where shareholders will vote on electing 10 directors, ratifying KPMG LLP as independent auditors for 2026, an advisory vote to approve named executive officer compensation, and approving the Amended and Restated 2023 Omnibus Incentive Plan. The record date is March 24, 2026, with 44,692,472 shares of Class A common stock outstanding and 952,463 unvested restricted shares entitled to vote. NBHC has engaged Alliance Advisors as proxy solicitor for approximately $35,000 plus reimbursable costs.

• ·Annual Meeting date and time: May 7, 2026 at 8:30 a.m. Central Time
• ·Meeting location: Vista Bank, a division of NBH Bank, 3225 Martin Luther King Jr. Boulevard, Dallas, TX 75210
• ·Record date for voting eligibility: March 24, 2026

03-04-2026

Twin Vee PowerCats Co. received a notification letter from Nasdaq on April 2, 2026, stating it no longer meets the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), based on closing bid prices below $1.00 for 30 consecutive business days from February 18, 2026, to March 31, 2026. Due to a prior 1-for-10 reverse stock split on April 7, 2025, the company is ineligible for a 180-calendar-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A). The company plans to request a hearing by April 9, 2026, to appeal, which would stay delisting pending the Panel's decision, though success is not assured.

• ·Deficiency period: 30 consecutive business days from February 18, 2026, to March 31, 2026
• ·Previous reverse stock split: 1-for-10 effective April 7, 2025
• ·Hearing request deadline: April 9, 2026
• ·Applicable rules: Nasdaq Listing Rule 5550(a)(2) and 5810(c)(3)(A)

03-04-2026

On March 30, 2026, Fidelity National Information Services, Inc. (FIS) was notified that Board Director Mark Benjamin will not stand for re-election at the 2026 annual meeting of shareholders, a decision not due to any disagreement with the Company's operations, policies, or practices. In connection with his departure, the Board approved reducing its size from ten to nine directors, effective immediately following the 2026 Shareholder Meeting. FIS's CEO Stephanie Ferris thanked Mr. Benjamin for his extraordinary contributions and dedication.

• ·Mr. Benjamin’s decision was not due to any disagreement with the Company on any matters relating to the Company’s operations, policies, or practices.

03-04-2026

Mondelez International, Inc. (MDLZ) filed DEFA14A Definitive Additional Proxy Soliciting Materials on April 03, 2026, as part of proxy statement activities ahead of a shareholder meeting. The document contains encoded proxy voting instructions and graphics but no discernible specific proposals or financial metrics. No period-over-period comparisons or performance data are present.

• ·Central Index Key: 0001103982
• ·Fiscal Year End: 1231
• ·State of Incorporation: IL
• ·Business Address: 905 West Fulton Market Street, Suite 200, Chicago, IL 60607

03-04-2026

Lyell Immunopharma, Inc. filed an S-3 registration statement on April 3, 2026, to register 1,952,360 shares of common stock for resale by selling stockholders, consisting of shares issued at the Milestone Closing of a July 24, 2025 private placement at $25.61 per share. The company will receive no proceeds from these resales and previously issued 3,753,752 shares at the Initial Closing at $13.32 per share. Selling stockholders include ARCH Venture Fund XIII, L.P., Euler Fund, L.P., Gates Frontier, LLC, and Explore Investments LLC, with post-offering beneficial ownership ranging from 4.0% to 11.8% based on 23,328,390 shares outstanding as of March 31, 2026.

• ·Selling stockholders have no current positions or offices with Lyell or affiliates, except historical board service by Robert Nelsen until May 2025.
• ·Company incorporated in June 2018; principal offices at 201 Haskins Way, South San Francisco, CA.
• ·Nasdaq symbol: LYEL.

03-04-2026

Drugs Made in America Acquisition Corp II (DMIIU) entered into a Definitive Investment and Sponsor Transition Agreement on March 23, 2026, with Tal Alpha Yezum Vekidum Asakim (2003) LTD for a total financing commitment of $1,400,000 to fund audit, SEC filings, Nasdaq fees, legal costs, and de-SPAC transaction preparation. Of this, $150,000 has been received, $300,000 is due by March 30, 2026, and $950,000 is reserved in escrow; however, the existing sponsor is described as non-performing and subject to legal constraints, necessitating a transition facilitated by the Company. The agreement includes a 4-month timeline to execute an investor-introduced transaction agreement in principle and 6-month exclusivity, with convertible notes at a 35% discount to post-merger market value.

• ·Exclusivity period: 6 months
• ·Timeline: Execute agreement in principle within 4 months
• ·Investor right of first refusal on additional capital beyond $1.4M
• ·No claim on trust account for convertible notes
• ·Maturity of Interim Convertible Note: 9 months from issuance
• ·Governing law: Cayman Islands
• ·Prior agreements superseded: LOI dated March 5, 2026; Addendum No. 1 dated March 9, 2026; Interim Convertible Note dated March 9, 2026; Sponsor Standstill Agreement dated March 18, 2026

03-04-2026

Edesa Biotech, Inc. filed Definitive Additional Proxy Materials (DEFA14A) on April 3, 2026, for its 2026 Annual General and Special Meeting on May 27, 2026, seeking shareholder approval for the election of seven directors, an advisory vote on executive compensation, amendment to the 2019 Equity Incentive Compensation Plan to increase available shares by 750,000 and remove the annual per-participant option limit, and appointment of MNP LLP as auditors. The Board recommends voting 'For' all proposals. No financial performance metrics or period comparisons are disclosed in the materials.

• ·Meeting location: 100 Spy Court, Markham, Ontario L3R 5H6, Canada
• ·Meeting time: May 27, 2026, 10:30 a.m. Eastern Time
• ·Vote deadline: May 26, 2026, 11:59 p.m. Eastern Time
• ·Materials request deadline: May 13, 2026

03-04-2026

Aurinia Pharmaceuticals Inc. (AUPH) announced a definitive merger agreement to acquire Kezar Life Sciences, Inc. (KZR) for $6.955 in cash per share plus a non-transferable contingent value right (CVR) linked to zetomipzomib development milestones, collaborations with Everest Medicines and Enodia Therapeutics, and net cash exceeding $50 million. The tender offer is set to commence by April 13, 2026, with closure expected in Q2 2026, supported by Tang Capital Partners (9.0% owner). While offering shareholder liquidity and strategic expansion in autoimmune therapies, the deal faces risks including closing conditions, potential delays, or termination.

• ·Tender offer requires majority of Kezar shares tendered and other customary conditions.
• ·Kezar board unanimously approved the merger following strategic review.
• ·Positive FDA Type C meeting interactions for zetomipzomib in AIH.

03-04-2026

David Chang resigned from the Board of Directors of Battalion Oil Corporation, including his role as Chairman of the Compensation Committee, effective March 31, 2026, and stated he will not stand for re-election. The resignation is explicitly not due to any disagreement with the Company on matters related to operations, policies, or practices.

• ·Resignation letter dated March 30, 2026
• ·Company address: 820 Gessner Road Suite 1100, Houston, Texas 77024

03-04-2026

Getty Images Holdings, Inc. appointed Jeffrey Titterton, a Board member since October 18, 2022, to its Audit Committee on April 3, 2026, determining he meets independence requirements under Rule 10A-3 and NYSE standards. James Quella resigned from the Board and Audit Committee effective April 1, 2026, with no disagreements on company operations, policies, or practices. The Board size remains at eleven directors, with the vacancy to be filled later.

• ·Jeffrey Titterton appointed to Board on October 18, 2022.
• ·James Quella resignation submitted March 31, 2026.
• ·Earliest event reported: March 29, 2026.

03-04-2026

Matinas BioPharma Holdings, Inc. received a notice from NYSE American on April 2, 2026, for failing to meet continued listing standards under Sections 1003(a)(i), (ii), and (iii) due to stockholders’ equity of $4.83 million as of December 31, 2025—below the required $2.0M, $4.0M, and $6.0M thresholds amid losses in its five most recent fiscal years. The company plans to submit a compliance plan by May 2, 2026, potentially gaining up to 18 months to cure the deficiency, with no immediate effect on its NYSE American listing or operations. However, compliance is not assured, and rejection of the plan could lead to delisting proceedings.

• ·Company not currently eligible for any exemption under Section 1003(a) of the NYSE American Company Guide.
• ·Shares of common stock (MTNB) continue to be listed and traded on NYSE American pending compliance with other listing requirements.

03-04-2026

VIDA Global Inc., a Delaware-incorporated emerging growth company in the AI sector (SIC 7372), filed an S-1 registration statement on April 2, 2026, for its initial public offering of 3,333,334 shares of Class A common stock at an estimated price of $4.50 to $5.00 per share (midpoint $4.75), with an underwriter over-allotment option for 500,000 additional shares. The company plans to list on NYSE American under the symbol 'VIDA', subject to approval. Post-offering, founders Lyle Pratt (CEO), Brandon Robinson (COO), and Timothy Noah Hayes (Chief Product Officer) will control 86.6% of voting power via Class B shares (86.0% if over-allotment exercised), making it a controlled company.

• ·Incorporated in Delaware (EIN: 88-1438776)
• ·Principal executive offices: 12160 W Parmer Ln, Ste 130-716, Cedar Park, TX 78613; phone: (833) 588-8432
• ·Classified as emerging growth company and smaller reporting company (non-accelerated filer)
• ·Class B common stock: 10 votes per share, convertible to Class A, subject to mandatory conversion events

03-04-2026

ITT Inc. delivered strong 2025 results with approximately $3.9 billion in sales across 125 countries, 10% total orders growth (5% organic) leading to a $1.9 billion backlog (+18% YoY), 8% revenue growth (5% organic), 11% adjusted operating income growth, and 14% adjusted EPS growth. The company generated $669 million in operating cash flow (17% margin) and $555 million in free cash flow (14% margin), deploying over $750 million in capital including $521 million in share repurchases and $111 million in dividends ($1.40 per share). In March 2026, ITT completed its largest-ever $4.775 billion acquisition of SPX FLOW ($4.075 billion cash + $700 million stock), strengthening its Flow Technologies segment.

• ·Annual meeting on May 21, 2026 at 9:00 a.m. ET virtually; record date March 25, 2026.
• ·Voting items: Elect 10 director nominees, ratify Deloitte & Touche LLP, advisory vote on NEO compensation.
• ·65% of 2025 revenue outside the U.S.
• ·Dividends increased 10% YoY to $1.40 per share.
• ·TSR of 23% in 2025 outperformed S&P 400 Capital Goods (+200 bps) and S&P 500 (+470 bps).
• ·Corporate governance includes independent Chair, majority voting, proxy access, no hedging/pledging.
• ·Engaged with shareholders representing ~44% of shares in Fall 2025.

03-04-2026

Western New England Bancorp, Inc. (WNEB) filed its DEF 14A definitive proxy statement on April 3, 2026, for the 2026 Annual Meeting of Shareholders on May 14, 2026 (record date March 16, 2026), seeking approval for director elections, a non-binding advisory vote on Named Executive Officer compensation, and ratification of Wolf & Company as independent auditors for the fiscal year ending December 31, 2026. The filing includes sections on board composition, corporate governance, executive compensation (with pay-versus-performance data for 2023-2025), director compensation, and security ownership, but no specific financial performance metrics or period-over-period changes are detailed in the provided content. As of the record date, 20,258,872 shares of common stock were outstanding.

• ·Annual Meeting location: Sheraton Springfield Monarch Place Hotel, One Monarch Place, Springfield, Massachusetts 01114 at 10:00 A.M. Eastern Daylight Time.
• ·Proxy materials available at wneb.q4ir.com/financials/proxy-materials and web.viewproxy.com/WNEB/2026.
• ·Shareholder proposals for 2027 Annual Meeting must be submitted by December 4, 2026.

03-04-2026

Bank of America highlighted robust 2025 performance in this DEFA14A proxy supplement, reporting Net Income of $30.5B (up 13% YoY), Revenue of $113.1B (up 7% YoY), diluted EPS up 19%, and ~250 bps of operating leverage, with strong growth across segments including Consumer Banking's ~680,000 net new checking accounts and $599B investment assets (up 16% YoY), Global Wealth & Investment Management's $4.8T client balances (up 12% YoY), and record Global Markets sales and trading revenue. The materials seek shareholder approval for 12 director nominees, Say on Pay vote, and ratification of PricewaterhouseCoopers LLP as auditor, while recommending votes against two shareholder proposals on independent board chair and animal welfare risk reporting. TSR reached 28% in 2025 following 34% in 2024.

• ·28 consecutive quarters of net new checking account growth in Consumer Banking.
• ·15 consecutive quarters of YoY sales and trading revenue growth in Global Markets.
• ·21 consecutive quarters of average loan growth in Global Markets.
• ·Global #3 investment banking fee ranking (Dealogic as of Dec 31, 2025).
• ·One of only 4 U.S. companies with over $15.0B Net Income in each of the last 11 years.
• ·Ranked #2 vs. primary competitors on 2025 Net Income, Revenue, and Market Capitalization.
• ·Shareholder outreach to 74 institutional shareholders representing ~45% of institutionally held shares.

03-04-2026

Pharmaceutical Resource Technology, Inc., a Wyoming-incorporated holding company with operations in Singapore, is filing an S-1/A amendment to register an offering of 100,000,000 shares of common stock at $0.50 per share on a self-underwritten, best-efforts basis, targeting net proceeds of $49,908,000 after $92,000 in expenses, with no minimum purchase requirement or escrow. The company operates in honey straw manufacturing (18% of revenue), pharmaceutical/dietary supplements manufacturing (18%), and building/construction (64%), heavily reliant on related-party Superbee Network Singapore Pte. Ltd. for operations, employing only two permanent staff. The offering highlights high speculative risks, including no established public market, penny stock rules, and potential operational disruptions from the related-party dependency.

• ·Incorporated June 17, 2019, as Jaison Phytochem, Inc.; renamed March 2023.
• ·Material operations commenced January 2020.
• ·Offering terminates upon sale of all shares or 365 days after effective date (extendable by 90 days).
• ·Intends to apply for quotation on OTCQB; no assurance of public market.
• ·Offering price arbitrarily determined, no relationship to assets or earnings.

03-04-2026

Denali Therapeutics Inc. (Nasdaq: DNLI) regained full rights and control of investigational therapy DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia (FTD-GRN) after Takeda terminated their co-development collaboration due to strategic considerations unrelated to efficacy or safety data. Denali plans to advance DNL593 independently using its TransportVehicle™ platform, with results from the ongoing Phase 1/2 study (enrollment complete with 40 participants) expected by end of 2026; interim data from healthy volunteers showed dose-dependent cerebrospinal fluid progranulin increases and good tolerability with no significant safety signals.

• ·Interim results from Part A of Phase 1/2 study in healthy volunteers: dose-dependent increases in cerebrospinal fluid progranulin levels, consistent with brain delivery; generally well tolerated with no significant safety signals.
• ·In animal models, TV platform enables 10- to 30-fold greater brain exposure for antibodies/enzymes; >1,000-fold for oligonucleotides in primates.
• ·FTD is most common dementia under age 60; GRN mutations are common genetic cause of FTD with no approved treatments to slow progression.

03-04-2026

CitroTech Inc. entered into a Transition Agreement with Stephen Conboy, its former Chief Technology Officer, effective March 31, 2026, transitioning him to an outside advisor role for a 90-day period ending June 30, 2026, with monthly payments of $10,000 and product advances up to $200,000. Post-transition, Conboy gains exclusive sales rights for specified products in a Tahoe-area territory subject to minimum gross sales thresholds of $500,000 in 2026 and $2,000,000 thereafter, along with equity provisions triggered by $10,000,000 financing or revenue milestones. His resignation from the CTO position was not due to any disagreements with the company.

• ·Transition Period: March 31, 2026 to June 30, 2026 (90 days)
• ·Exclusive sales territory: near North Lake Tahoe, South Lake Tahoe, and Truckee, California
• ·Agreement includes broad release of claims, confidentiality, non-disclosure, restrictive covenants, and non-disparagement provisions
• ·Post-transition affiliate agreement to be negotiated for commissions on net sales in defined territory

03-04-2026

Bank7 Corp. (BSVN) filed a Definitive Proxy Statement (DEFA14A) on April 03, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is not confidential or preliminary soliciting material. No specific proposals, financial data, or voting matters are detailed in the provided content.

03-04-2026

Eagle Bancorp, Inc. (EGBN) filed a DEFA14A Definitive Additional Proxy Materials on April 03, 2026, as part of Schedule 14A under Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and appears to be a notice and access card (based on filename). No specific financial data, proposals, or other substantive details are provided in the extracted content.

03-04-2026

On March 31, 2026, the Board of Directors of Global-Smart.Tech Inc. appointed Leonel Agustin Peleriti as an Independent Director, effective immediately. Mr. Peleriti, a former Technology Solutions Analyst at Mercado Libre (2020-2023) with a Bachelor’s degree in Information Systems Engineering from the National University of Córdoba, was confirmed to meet OTC Markets independence standards with no material conflicts, family relationships, or transactions exceeding $120,000. The Company is an emerging growth company with principal offices in Tivat, Montenegro.

• ·Company incorporated in Wyoming (IRS EIN: 98-1664763; Commission File Number: 000-56781)
• ·Principal executive offices: Yehor Rodin Kava b.b., 85320, Tivat, Montenegro; Phone: +1-205-2165924
• ·No securities registered pursuant to Section 12(b) of the Act
• ·No family relationships between Mr. Peleriti and any directors or executive officers
• ·No material plan, contract, or arrangement involving the new director in connection with the appointment

03-04-2026

At Hewlett Packard Enterprise Company's 2026 Annual Meeting on April 1, 2026, stockholders elected all 12 director nominees with strong majorities (ranging from ~95% to ~99% votes for), ratified Ernst & Young LLP as auditors with 98% support, and approved Amendment No. 5 to the 2021 Stock Incentive Plan increasing shares reserved by 22 million. However, the advisory vote on executive compensation passed with only 74% support amid 264 million votes against, and a stockholder proposal on discrimination reporting failed overwhelmingly with just 1% support.

• ·Broker non-votes: 157,291,562 across director elections, Proposals 3, 4, and 5
• ·Proposal 2 (auditor ratification): 1,143,409,866 votes for, 18,711,455 against
• ·Patricia F. Russo received the highest against votes among directors (47,841,595)

03-04-2026

SouthState Bank Corporation (NYSE: SSB) announced on April 3, 2026, that it will release its first quarter 2026 earnings results on Thursday, April 23, 2026, after market close. The company will host a conference call on Friday, April 24, 2026, at 9:00 a.m. ET, hosted by CFO Will Matthews, with dial-in options and a live webcast available via the Investor Relations section of www.SouthStateBank.com. No financial results or metrics were disclosed in this filing.

• ·Conference call dial-in: (888) 350-3899 (US toll-free), (646) 960-0343 (international); Conference ID: 4200408.
• ·Pre-registration link: https://events.q4inc.com/attendee/361570488.
• ·International participant numbers: https://events.q4irportal.com/custom/access/2324/.
• ·Audio replay available by evening of April 24, 2026, on the website.

03-04-2026

Benchmark 2019-B14 Mortgage Trust filed an 8-K announcing that the special servicer for The Essex Mortgage Loan, constituting approximately 4.3% of the asset pool as of the cut-off date, was changed from Midland Loan Services (a Division of PNC Bank, National Association) to KeyBank National Association, effective April 3, 2026, pursuant to Section 7.01(d) of the BMARK 2019-B14 PSA dated November 1, 2019. This procedural change is in the interest of transaction management with no reported impact on performance metrics.

• ·KeyBank principal servicing offices located at 11501 Outlook Street, Suite 300, Overland Park, Kansas 66211.
• ·Pooling and servicing agreement originally filed as Exhibit 4.1 to Form 8-K/A on December 17, 2019.

03-04-2026

Global Wealth Strategies & Associates, an investment advisor based in Denver, CO, filed its 13F-HR report disclosing $406,982,747 in total holdings across 543 positions as of March 31, 2026, all held with sole discretionary authority. Top holdings include Vanguard S&P 500 ETF at $122,325,310 (204,711 shares), iShares U.S. Equity Factor Rotation Active ETF at $20,688,284 (355,591 shares), and Schwab U.S. Small-Cap ETF at $8,313,909 (285,898 shares). The portfolio features a diversified mix of equities, ETFs, and fixed income products with no period-over-period changes disclosed in this filing.

• ·Filing submitted on April 3, 2026, for period ending March 31, 2026.
• ·CIK: 0001912297; SEC File Number: 028-22730.
• ·Business address: 3200 Cherry Creek South Drive, Suite 280, Denver, CO 80209.

03-04-2026

Camden National Corporation's definitive proxy statement for the 2026 Annual Meeting of Shareholders, to be held virtually on May 19, 2026, seeks approval for the election of eleven directors for one-year terms, a non-binding advisory 'Say-on-Pay' vote on named executive officer compensation, and ratification of RSM US LLP as independent auditors for the year ending December 31, 2026. The record date for shareholders entitled to vote is March 25, 2026. No financial performance metrics, period-over-period comparisons, or compensation figures are detailed in the provided filing content.

• ·Annual Meeting date: Tuesday, May 19, 2026, at 9:00 a.m. Eastern Daylight Time, virtual via www.virtualshareholdermeeting.com/CAC2026.
• ·Record date: Close of business on March 25, 2026.
• ·Filing date: April 3, 2026.

03-04-2026

Situs Holdings, LLC was removed as special servicer for the Potomac Mills Mortgage Loan, which constitutes approximately 8.9% of the CFCRE 2016-C6 Mortgage Trust's asset pool as of the cut-off date, and Torchlight Loan Services, LLC was appointed as successor special servicer effective April 3, 2026, pursuant to the CFCRE 2016-C6 PSA. Torchlight has extensive experience, having resolved over $12.2 billion in U.S. commercial and multifamily loans since 1998 and managing a growing portfolio with named specially serviced UPB increasing from $6.68B as of 12/31/2022 to $18.36B as of 12/31/2025; however, its actively specially serviced portfolio UPB grew more modestly from $461.5M to $3.08B over the same period while personnel dedicated to special servicing remained limited at 4 out of 21 as of 12/31/2025.

• ·Change effective pursuant to Section 3.22(i) of the CFCRE 2016-C6 PSA dated November 1, 2016.
• ·Torchlight has no material primary advancing obligations and no known material legal proceedings.
• ·Torchlight is not an affiliate of key parties and owns no Certificates in the issuing entity.

03-04-2026

CFCRE 2016-C7 Mortgage Trust announced via 8-K that Situs Holdings, LLC was removed as special servicer for the Potomac Mills Mortgage Loan, which represents approximately 6.2% of the asset pool as of the cut-off date, and Torchlight Loan Services, LLC was appointed as successor special servicer effective April 3, 2026, under the CFCRE 2016-C6 PSA. This change is in the interest of transaction management with no disclosed financial impacts or performance metrics. The filing provides Torchlight's contact details for special servicing.

• ·Pooling and Servicing Agreement (PSA) dated November 1, 2016
• ·Torchlight principal office: 90 Park Avenue, 20th Floor, New York, New York 10016; Phone: 212-883-2800